Literature DB >> 33227519

The effects of Japan's National Action Plan on Antimicrobial Resistance on antimicrobial use.

Yoshiki Kusama1, Shinya Tsuzuki2, Yuichi Muraki3, Ryuji Koizumi4, Masahiro Ishikane5, Norio Ohmagari6.   

Abstract

The aim of this study was to estimate the effects of Japan's National Action Plan on Antimicrobial Resistance 2016-2020 (NAP) on antimicrobial use (AMU). Monthly AMU from January 2013 to December 2019 was calculated using sales data, and time-series charts of AMU were then created for the total antimicrobials and target drug categories shown in the NAP (oral cephalosporins, oral fluoroquinolones, oral macrolides, and parenteral antimicrobials). Twelve-month predictions were generated to evaluate AMU in 2020. The publication of the NAP was associated with an AMU reduction in total antimicrobials, cephalosporins, fluoroquinolones, and macrolides. Parenteral AMU showed an upward trend, although it was not significantly associated with the intervention effect. AMU reductions of 15.0% for total antimicrobials, 26.3% for cephalosporins, 23.5% for fluoroquinolones, and 24.6% for macrolides were predicted for 2020 relative to 2013. However, there was a predicted increase of 17.4% for parenteral AMU. While Japan's NAP has contributed to the reduction in national AMU over the past 5 years, sustained action is still needed to further improve antimicrobial stewardship and promote countermeasures to antimicrobial resistance.
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Antimicrobial resistance; Antimicrobial use; Interrupted time-series analysis; National action plan

Year:  2020        PMID: 33227519     DOI: 10.1016/j.ijid.2020.11.158

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  5 in total

1.  Exploration of Trends in Antimicrobial Use and Their Determinants Based on Dispensing Information Collected from Pharmacies throughout Japan: A First Report.

Authors:  Yuichi Muraki; Masayuki Maeda; Ryo Inose; Koki Yoshimura; Naoki Onizuka; Masao Takahashi; Eiji Kawakami; Yoshiaki Shikamura; Naotaka Son; Makoto Iwashita; Manabu Suzuki; Masayuki Yokoi; Hirokazu Horikoshi; Yasuaki Aoki; Michiyo Kawana; Miwako Kamei; Hajime Hashiba; Choichiro Miyazaki
Journal:  Antibiotics (Basel)       Date:  2022-05-18

2.  Trend of Antibiotic Use in Children with Acute Otitis Media in Korea.

Authors:  Kyu Hyun Park; Seung-Ah Choe; Ju-Young Shin; Young June Choe
Journal:  J Korean Med Sci       Date:  2021-11-29       Impact factor: 2.153

3.  Antimicrobial Use Fell Substantially in Japan in 2020-The COVID-19 Pandemic May Have Played a Role.

Authors:  Akane Ono; Ryuji Koizumi; Shinya Tsuzuki; Yusuke Asai; Masahiro Ishikane; Yoshiki Kusama; Norio Ohmagari
Journal:  Int J Infect Dis       Date:  2022-03-17       Impact factor: 12.074

4.  Prevalence and changes of low-value care at acute care hospitals: a multicentre observational study in Japan.

Authors:  Atsushi Miyawaki; Ryo Ikesu; Yasuharu Tokuda; Rei Goto; Yasuki Kobayashi; Kazuaki Sano; Yusuke Tsugawa
Journal:  BMJ Open       Date:  2022-09-07       Impact factor: 3.006

5.  Estimating the Economic and Clinical Value of Introducing Ceftazidime/Avibactam into Antimicrobial Practice in Japan: A Dynamic Modelling Study.

Authors:  Tetsuya Matsumoto; Akira Yuasa; Ryan Miller; Clive Pritchard; Takahisa Ohashi; Amer Taie; Jason Gordon
Journal:  Pharmacoecon Open       Date:  2022-09-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.